EA202190617A3 - Соединения-ингибиторы бета-лактамаз - Google Patents

Соединения-ингибиторы бета-лактамаз

Info

Publication number
EA202190617A3
EA202190617A3 EA202190617A EA202190617A EA202190617A3 EA 202190617 A3 EA202190617 A3 EA 202190617A3 EA 202190617 A EA202190617 A EA 202190617A EA 202190617 A EA202190617 A EA 202190617A EA 202190617 A3 EA202190617 A3 EA 202190617A3
Authority
EA
Eurasian Patent Office
Prior art keywords
lactamaz
beta
inhibitor compounds
inhibitor
compounds
Prior art date
Application number
EA202190617A
Other languages
English (en)
Other versions
EA202190617A2 (ru
Inventor
Жанель Комита-Превуар
Тома Франсуа Дюран-Ревий
Лиз Готье
Джон О'Доннелл
Ян Ромеро
Рубен Томмаси
Ерун Кюнера Верхейен
Франк У
Сяоюнь У
Цзин Чжан
Грегори С. Басараб
Билл Мосс
Original Assignee
Энтасис Терапеутикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энтасис Терапеутикс Лимитед filed Critical Энтасис Терапеутикс Лимитед
Publication of EA202190617A2 publication Critical patent/EA202190617A2/ru
Publication of EA202190617A3 publication Critical patent/EA202190617A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
EA202190617A 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз EA202190617A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762456423P 2017-02-08 2017-02-08

Publications (2)

Publication Number Publication Date
EA202190617A2 EA202190617A2 (ru) 2021-06-30
EA202190617A3 true EA202190617A3 (ru) 2021-10-29

Family

ID=67734930

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990738A EA037916B1 (ru) 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз
EA202190617A EA202190617A3 (ru) 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990738A EA037916B1 (ru) 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз

Country Status (1)

Country Link
EA (2) EA037916B1 (ru)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
PL2748165T3 (pl) * 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
JP6764862B2 (ja) * 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法

Also Published As

Publication number Publication date
EA037916B1 (ru) 2021-06-07
EA201990738A1 (ru) 2019-08-30
EA202190617A2 (ru) 2021-06-30

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3601283T3 (da) Kondenseret imidazo-piperidin-JAK-inhibitorforbindelse
MA54550A (fr) Inhibiteurs de kif18a
DK3442972T3 (da) Bromdomænehæmmere
DK3728252T3 (da) 4-azaindolforbindelser
DE202018003363U8 (de) Handgelenkssphygmomanometer
GB201705971D0 (en) Inhibitor compounds
CL2018000524S1 (es) Golilla
MA44006A (fr) Inhibiteur pde1
MA52812A (fr) Inhibiteurs de sarm1
DK3351526T3 (da) Diisopentylterephthalat
DK3612519T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
DK3571192T3 (da) Jak1-selektive inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3668955T3 (da) Korrosionsinhibitor
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3562487T3 (da) Metalloenzyminhibitorforbindelser
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
DK3630752T3 (da) Substituerede nitrogenholdige forbindelser
DK3597189T3 (da) Krystallinske forbindelser
MA51611A (fr) Inhibiteurs de pi4kiiibêta
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer